Back to All Combinations

PIK3CA Exon 9

Intermediate Prognosis
8.00% Prevalence Level 3 PIK3CA Pathway
Genes Involved
PIK3CA
Treatment Implications

PI3K pathway activation. Aspirin benefit unclear for exon 9.

Recommended Treatments
Standard chemotherapy
Clinical trials
Treatments to Avoid

No specific contraindications noted

Study References

Liao et al

Key Statistics
8.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Different biology than exon 20.
Information

Category: PIK3CA Pathway

Evidence Level: Level 3

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.